Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XB003
- Development stage
- Preclinical
- Lead developer
- Alvotech
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
XB003 is a biosimilar drug candidate referencing Cimzia (certolizumab pegol), a tumor necrosis factor alpha (TNFα) inhibitor primarily used in the treatment of rheumatoid arthritis and psoriasis. Cimzia is also notable for its use in pregnant and breastfeeding women due to its unique molecular structure. XB003 has been developed using Xbrane's patented platform technology designed for high-yield and low-cost production. Analytical similarity to the reference product has been demonstrated, and the program is ready to initiate clinical trials as of 2025. The drug was originally developed by Xbrane Biopharma but was acquired by Alvotech in March 2025[1][2][3][4][5][9].
- Other names
- certolizumab pegol biosimilarCimzia biosimilar candidate
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on XB003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XB003.